Fractyl Health, Inc. (NASDAQ:GUTS) Short Interest Up 5.7% in July

Fractyl Health, Inc. (NASDAQ:GUTS) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totalling 2,430,000 shares, a growth of 5.7% from the July 15th total of 2,300,000 shares. Approximately 12.2% of the company’s stock are short sold. Based on an average trading volume of 244,600 shares, the days-to-cover ratio is currently 9.9 days.

Fractyl Health Trading Up 1.7 %

Shares of NASDAQ:GUTS traded up $0.04 during trading hours on Friday, hitting $2.39. The company’s stock had a trading volume of 227,719 shares, compared to its average volume of 292,404. The company’s fifty day moving average is $4.06. Fractyl Health has a 52 week low of $1.74 and a 52 week high of $14.50. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.37 and a current ratio of 9.38.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.10. The business had revenue of $0.04 million during the quarter. Equities analysts anticipate that Fractyl Health will post -2.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

A number of hedge funds have recently made changes to their positions in GUTS. Rhumbline Advisers purchased a new position in Fractyl Health in the second quarter worth $32,000. Renaissance Technologies LLC acquired a new position in Fractyl Health during the 2nd quarter valued at approximately $61,000. Massachusetts Financial Services Co. MA raised its holdings in shares of Fractyl Health by 2.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock worth $4,255,000 after buying an additional 25,829 shares during the last quarter. American International Group Inc. purchased a new stake in Fractyl Health during the first quarter worth $9,911,000. Finally, M28 Capital Management LP purchased a new position in Fractyl Health in the first quarter valued at $13,735,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.